patent cliff

Pharmaceutical companies will suffer an estimated $65 billion drop in sales by 2019 due to the patent expiries of several leading drugs, according to research and consulting firm GlobalData. Read more

Camargo Pharmaceutical Services’s Ready 4 Action assessment enables drug developers — generic companies in particular — to identify viable products to bring to market. Camargo will be exhibiting at the Generic Pharmaceutical Association (GPhA)... Read more


What pharma companies are doing to avoid another cliffhanger

Haydn Evans is vice president of intellectual property solutions at CPA Global, one of the world’s leading providers of IP management software and services. He works with a range of clients in sectors such as technology, telecommunications... Read more

31 Jan 2014 15:01 Guest Blogs